Actively Recruiting
Study of GZ17-6.02 to Delay Progression in Advanced Castration-Resistant Prostate Cancer After Anti-Androgen Therapy
Led by Virginia Commonwealth University · Updated on 2026-01-27
30
Participants Needed
1
Research Sites
235 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate whether GZ17-6.02 can delay the progression of castration-resistant prostate cancer in men who have previously undergone androgen deprivation therapy and treatment with an androgen receptor pathway inhibitor. It is a phase Ib single-arm study focusing on men with advanced prostate cancer that no longer responds to hormone therapies. The study also aims to assess the safety and tolerability of GZ17-6.02 while exploring patient-reported outcomes. Participants will receive GZ17-6.02 orally at a fixed dose of 375 mg twice daily with a high-fat meal, following a 28-day cycle that continues until disease progression or intolerable side effects occur. This study involves only one treatment group where all participants receive the investigational agent. The treatment is a combination of curcumin, harmine, and isovanillin. There is no placebo or comparison group. During the study, participants will be monitored through imaging scans such as CT and bone scans to assess disease progression. Researchers will measure radiologic progression-free survival over 6 months and up to 5 years after treatment ends. Other evaluations include biochemical responses, duration of tumor response, overall survival, and safety assessments up to 5 years post-treatment. Participants will have follow-up visits including a 30-day safety check after treatment completion.
CONDITIONS
Brief Title
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
Research Team
M
Massey IIT Research Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here